Form: SC 13D

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

July 9, 2021

Exhibit 1

Joint Filing Agreement

The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Graphite Bio, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.

 

July 9, 2021

Versant Venture Capital VI, L.P.

By:

 

Versant Ventures VI GP, L.P.

Its:

 

General Partner

By:

 

Versant Ventures VI GP-GP, LLC

Its:

 

General Partner

By:

 

/s/ Robin L. Praeger, Managing Director

Versant Ventures VI GP, L.P.

By:

 

Versant Ventures VI GP-GP, LLC

Its:

 

General Partner

By:

 

/s/ Robin L. Praeger, Managing Director

Versant Ventures VI GP-GP, LLC

By:

 

/s/ Robin L. Praeger, Managing Director

Versant Vantage II, L.P.

By:

 

Versant Vantage II GP, L.P.

Its:

 

General Partner

By:

 

Versant Vantage II GP-GP, LLC

Its:

 

General Partner

By:

 

/s/ Robin L. Praeger, Managing Director

Versant Vantage II GP, L.P.

By:

 

Versant Vantage II GP-GP, LLC

Its:

 

General Partner

By:

 

/s/ Robin L. Praeger, Managing Director

Versant Vantage II GP-GP, LLC

By:

 

/s/ Robin L. Praeger, Managing Director